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The objective of the current research was to review and update evidence on the dietary effect of the consumption of tagatose in type
2 diabetes, as well as to elucidate the current approach that exists on its production and biotechnological utility in functional food
for diabetics. Articles published before July 1, 2017, were included in the databases PubMed, EBSCO, Google Scholar, and Scielo,
including the terms “Tagatose”, “Sweeteners”, “Diabetes Mellitus type 2”, “Sweeteners”, “D-Tag”. D-Tagatose (D-tag) is an isomer
of fructose which is approximately 90% sweeter than sucrose. Preliminary studies in animals and preclinical studies showed that
D-tag decreased glucose levels, which generated great interest in the scientific community. Recent studies indicate that tagatose
has low glycemic index, a potent hypoglycemic effect, and eventually could be associated with important benefits for the treatment
of obesity. The authors concluded that D-tag is promising as a sweetener without major adverse effects observed in these clinical
studies.
1. Introduction
D-Tagatose (D-tag) is an isomer of fructose which is approx-
imately 90% sweeter than sucrose. Fructose that corresponds
to a natural hexose was developed as a low-calorie sugar
substitute.
Only 20% of the orally ingested tagatose is metabolized
completely and mainly in the liver [1]. In 2001, D-tag was
appointed by the Food and Drug Administration (FDA) as a
generally recognized safe product (GRAS), and subsequently
it has been used as a nutritional sweetener or low in calories
[2]. After this, the European Union (EU) introduced D-tag
as a “new food ingredient,” without any restrictions on the
amount to be used [1, 2].
Currently, D-tag is used as a sweetener in beverages,
yogurt, creams, and dietetic candy [3].
Amethod for themature production of D-tag is the direct
isomerization of G-galactose in D-tag, withmetal hydroxides
such as chemical catalysts in basic conditions [4].
Preliminary animal studies and preclinical studies
showed that D-tag decreased glucose levels, generating
great interest in the scientific community [5]. The pro-
posed action mechanism may involve interference in the
absorption of carbohydrates through inhibition of intestinal
disaccharidases and glucose transportation. It can also act
through the inhibition of hepatic glycogenolysis [1]. In
addition to presenting an effect in the reduction of total
cholesterol, VLDL, and LDL compared with sucrose [6],
likewise D-tag has contributed to increasing levels of HDL
cholesterol [7].
The D-tag would have an antihyperglycemic potential
through its beneficial effects on the increment of postprandial
serum glucose and hyperinsulinemia. Recent studies indicate
that tagatose has a powerful antidiabetic effect and could
eventually be associated with important benefits for the
treatment of obesity. However, preliminary results of a study
indicated that there were not any changes in glucose or
insulin levels after oral administration of D-tag while fasting
[8].
The objective of this research is to review and update
evidence about the therapeutic effect of the consumption
of tagatose in patients with diabetes type 2 as well as to
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Table 1: Antihyperglycemic effect of D-tagatose.
Sample population Methodology Findings Mechanism described orproposed
Normal subjects and
type 2 diabetics patients.
They were given 75 g of glucose, 75 g of
D-tag, or 75 g of D-tag 30min prior to
a 75 g oral glucose tolerance test.
The glucose area under the curve
(AUC) was reduced significantly also
by pretreatment with D-tag in a
dose-dependent manner in patients
with diabetes mellitus (𝑃 < 0.05 for
10 g D-tag, 𝑃 < 0.001 for 20 g D-tag,
and 𝑃 = 0.0001 for 30 g D-tag) [8].
D-Tagatose directly inhibits
the absorption of glucose
by intestinal
disaccharidases.
Type 2 diabetics patients.
They were given D-tag in three
treatment groups: 2.5 g, 5.0 g, and 7.5 g
given orally (three times daily,
immediately prior to meals). Eight
weeks after screening and stabilization
of diabetics.
Only the 7.5 g dosage group exhibited
reductions of fasting glucose from
baseline at the 3- and 6-month time
points [1].
Inhibition of sucrose
activity by D-tag has been
in rabbit small intestine.
Type 2 diabetics patients.
Two randomized groups were given a
dose of D-tag (15 g) and the other
group was given a dose of placebo
(1.5 g), which were dissolved in 125 to
250ml of water three times a day (TD).
D-Tagatose significantly reduced
HbA1c compared to placebo.
D-Tagatose was effective at reducing
the HbA1c level when administered for
two months at doses of 15 g TID.
Also significant reductions in the
HbA1c level at six and ten months
were also met [9].
Unlike many other diabetes
drugs, the longer the
D-tagatose therapy, the
better the efficacy, since the
intestinal mucosa will be
exposed for a longer period
to D-tag.
elucidate the current approach that exists on its production
and biotechnological use in functional food for diabetics.
2. Methodology
Articles published before July 1, 2017, were selected for the
completion of this review; the search was carried out in
the databases PubMed, EBSCO, Google Scholar, and Scielo,
including terms or key words “Tagatose”, “Sweeteners”, “Dia-
betes Mellitus type 2”, “Sweeteners”, “D-Tag”.
This review included clinical interventions in animals and
humans, as well as studies on the formulation and production
of food that contain tagatose.The search includedEnglish and
Spanish as languages.
3. Tagatose and Blood Glucose
A phase II study with more than 6 months of duration and
a phase III effectiveness study with more than 12 months of
duration used D-tag to reduce HbA1c in 161 and 494 diabetic
patients, respectively, in the United States and India. The
results showed a statistically significant reduction in HbA1c
compared to the placebo group, concluding that it could
eventually become a treatment for diabetes [10].
A cross, randomized, double-blind experimental design
determined the supplementation effect with tagatose on
postprandial hyperglycemia in 85 Korean hyperglycemic
individuals (𝑛 = 52 and 𝑛 = 33) [1] (Table 1). Blood samples
were taken during fasting and after drinking a beverage with
sucralose-erythritol (placebo) and other formulation with
tagatose at 0, 30, 60, and 120 minutes, analyzing glucose,
insulin, C-peptide, and lipid profile [1]. Hyperglycemic indi-
viduals of legal age had higher levels of triglycerides, Col-
total, LDL-Col, A1, and B apolipoprotein. After the intake of a
beverage with tagatose (5 g), only hyperglycemic individuals
had a significant reduction of blood glucose at 120min
(𝑃 = 0.019), as well as in the blood glucose area under
the curve (AUC) (𝑃 = 0.017) [1]. Normal individuals who
received a high dose of the beverage with tagatose (10 g)
showed decreased levels of serum insulin, AUC of insulin,
and C-peptide. Therefore, these results suggest that a bever-
age sweetened with tagatose could control the postprandial
glycemic response in individuals with hyperglycemia [1].
Another study [11] was performed to investigate acute
effects on blood sugar levels in 8 healthy individuals and in
8 individuals with DM 2, after the oral intake of 75 g of D-
tagatose (D-tag) alone and combined with 75 g of glucose.
Diabetics received separately and at 0, 10, 15, 20, and 30min
75 g of D-tag, 30 minutes before a dose of 75 g of glucose.
Oral load with D-tag did not alter blood sugar levels or
insulin in any group. The pretreatment with 75 g of D-tag
attenuated the glycemic curve in diabetics [11], significantly
reducing the blood glucose area under the curve (AUC)
and the glycemic increment after the ingestion of glycoside
solution [11]. Gastrointestinal adverse effects caused by high
doses of D-tag suggest that this may act to reduce intestinal
glucose absorption.
In another randomized research [12] whose main objec-
tive was to evaluate the safety and effect of D-tag on the
glycemic control in patients with DM 2 according to levels of
glycosylated hemoglobin (HbA1c) at the endof 6monthswith
different doses of D-tag, 2.5 g, 5.0 g, or 7.5 g (3 times/day),
controlling the serum level of blood glucose, plasma lipids,
HbA1c, changes in body weight, and body mass index, as
well as insulin variations [12], basal glycaemia dropped in
3 and 6 months just in the group that received a dose of
7.5 g. The average body weight dropped directly in greater
proportion to doses of 5.0 g and 7.5 g of D-tag.Theminimum






Figure 1: D-Tagatose glycemic control; proposed mechanism
explained that D-tagatose directly inhibits the absorption of glucose
by intestinal disaccharidases. Note. Marion Guerrero-Wyss, Samuel
Dura´n Agu¨ero, Lisse Angarita Da´vila, 2017.
amount necessary to reduce theHbA1c corresponded to 5.0 g,
while the highest dose (7.5 g) provided a greater effect on the
evaluated parameters [12].
3.1. Proposed Mechanisms of the Metabolic Effect of D-Tag.
It should be noted that the mechanisms related to the
effect of D-tagatose on the regulation of glycaemia are still
under study. However, some authors have described various
mechanisms by which the antihyperglycemic effect of D-
tagatose could be explained, highlighting a direct inhibition
of intestinal disaccharidases, which would increase as the
period of intestinal exposure increases to D-tagatose (Fig-
ure 1).
Another proposed hypothesis could be explained through
the inhibition of hepatic glycogenolysis [1] (Figure 2).
Tagatose seems to act by promoting glycogen synthesis and to
decrease glycogen utilization. Sudhamani Muddada explains
that D-tag competitively inhibits the enzyme that metab-
olizes glycogen [13], causing glucose to remain stored as
glycogen. On the other hand, it promotes the metabolism of
glucose to glucose-6-P, which stimulates storage of glucose as
glycogen. The intermediate of tagatose metabolism tagatose-
1-phosphate promotes the activity of glucokinase, resulting in
increased phosphorylation of glucose to glucose-1-phosphate
which activates glycogen synthase mobilising glucose to
glycogen. Tagatose-1-phosphate inhibits the activity of glyco-
gen phosphorylase preventing glycogen breakdown. It is
hypothesised that tagatose is metabolized like fructose but
at a slower rate [13]. Also, tagatose prevents absorption of
sucrose and maltose by inhibiting the action of sucrases and
maltases in the small intestine [1].
On the other hand, the interaction of ingested nutrients
with the small intestine to stimulate the release of gut pep-
tides, including glucagon-like peptide 1 (GLP-1) and glucose-
dependent insulinotropic polypeptide (GIP), represents a
major mechanism in the regulation of gastric emptying,
satiety, and insulin secretion [11]. In this sense, the capacity
of tagatose to increase GLP-1 secretion is highly relevant to
the lowering of blood glucose. D-tag is reported to stimulate
GLP-1 to a comparable degree to fructose, whereas it did not
stimulate GIP [11]. Because neither fructose nor tagatose is
sodium-glucose cotransporter-1 (SGLT1) substrate, it follows
that signaling pathways other than SGLT1 are likely to be
involved inGLP-1 secretion.The exposure of poorly absorbed
sugars to the distal gut, with the production of short-
chain fatty acids by bacterial fermentation, may represent
an important mechanism of GLP-1 stimulation [14]. Xylose,
a poorly absorbed pentose, is a potent stimulus for GLP-1,
and tagatose may act in a similar manner, given its relatively
low absorption rate (∼25%). Wu et al. [15] showed that,
in healthy humans, the preloads with tagatose/isomaltose
(TIM), partially absorbed, promoted a prolonged secretion
of GLP-1; this is probably stimulated by a long length in gut
and therefore results in later GLP-1 secretion but does not
stimulateGIP.Nevertheless, GLP-1was stimulated to a greater
level by the TIM than bythe sucralose preload immediately
after the meal, and tagatose was also shown to slow gastric
emptying rapidly [15], so that early gastrointestinal responses
to tagatose might be mediated by other pathways, such as
GLUT5 (the fructose transporter) [15].
On the other hand, a positive effect of D-tag in the
reduction of total cholesterol, VLDL, and LDL compared
with sucrose has been reported [6]. The proposed action
mechanism may involve reduced pyruvate generation from
glycolysis, reducing acetyl CoA through the Krebs cycle
as a precursor to cholesterol [13]. Some authors have also
described that D-tag has contributed to increasing levels
of HDL cholesterol [7]. Recently, it was suggested that D-
tagatose blocks absorption of fructose through the gut and
can effectively reduce diet-induced dyslipidemia [13].
4. Toxicity of D-Tagatose
A study was conducted to detect toxicity of D-tag in rats (SD)
[16], administering D-tag in three doses (4,000, 12,000, and
20,000mg/kg body weight/day) through gastric intubation
on days 6 to 15 of gestation period. Related toxicity or clinical
effects associated inmaternal rats at a dose of 4000mg/kg/day
were not observed. In the mid and high doses, nonformed
stools were observed; this effect was more prominent in the
early period of treatment (6th to 8th day) attributed to the
osmotic action of the big quantity administered of D-tag.
This molecule is not well digested or absorbed; most part of
the sugar goes to the colon, where it absorbs water and is
fermented by colonic bacteria. The group submitted to the
highest dose experienced an average weight loss during the
interval from the 6th to the 9th day of gestation, considered
as a direct result of the laxative effect. In addition to this
action, the reduced consumption of food also contributed to
the decrease in weight gain. Animals exposed tomedium and
high dose presented one food intake less than the control
group. Adverse effects on reproductive performance were
not observed in treatment groups or in the fetus overweight,
neither in the distribution by sex, weight of the liver, nor
external, visceral, or skeletal malformations in any dose [16].
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Figure 2: D-Tagatose glycemic control; proposedmechanism explained through the inhibition of hepatic glycogenolysis.Note. Adapted from
the original “Tagatose Glycemic Control MOA in the Liver” produced by Muddada, 2012 [13].
The potential genotoxic effect of this molecule was exam-
ined in five standard trials [17]. In these tests, there was
not any significant increment in the ovary cells of Chinese
hamster with chromosomal alterations in concentrations up
to 5000mcg/ml with or without metabolic activation. It
was not found that D-tag could increase the frequency of
lymphoma cancer cells of mouse L5178Y with or without
metabolic activation; additionally, D-tag did not modify
micronucleus of polychromatic erythrocytes in the bone
marrow, concluding that this molecule was not genotoxic in
the trials described above [17].
Another clinical, cross, and double-blind study evaluated
the effect of this monosaccharide against D-fructose on the
increment in the production of uric acid [18], through the
acceleration of purine nucleotide degradation as well as other
metabolic parameters in 8 male individuals. It was detected
that both the highest concentration of uric acid and the 4-
hour AUC were significantly higher after the intake of D-
tag compared to 30 g D-fructose or water. It is concluded
that D-tag attenuates glycemic and insulin response of a food
255 minutes after its ingestion. In addition, both sweeteners
increased cholecystokinin (CCK) and peptide levels similar
to glucagon-1 (GLP-1).
In the same two-phase investigation mentioned above
[18] carried out in 8 healthy individuals and in 8 individuals
with diabetes type 2, the effect of repeated doses of D-tag in
urea, phosphorus, magnesium, lipids, and glycemic home-
ostasis was determined. In the first phase, 75 g of glucose
was administered and oral tolerance of glucose and D-tag
test was assessed. Uric acid, phosphorus, and magnesium
levels were determined in blood samples collected at 0, 30,
60, 120, and 180 minutes after the intake. Healthy individuals
received at random 75 g of D-tag or sucrose (25 g with each
meal) per day for 8 weeks. Diabetics were assigned into two
groups and received 75 g of D-tag or a supplement without
sugar every day for 8 weeks. This test did not show a basal
increment of uric acid in response to the daily intake of D-
tag. However, a transient increase in the plasma level of uric
acid was observed after the single dose of 75 g of D-tag in the
tolerance test at 60 minutes. In accordance with the previous
observations on the fructose, the increment of uric acid in
plasmawas associated with a slight decrease of phosphorus in
plasma and a slight increase of magnesium. The daily intake
ofD-tag for 8weeks did not have any effect on themagnesium
in plasma in fasting, phosphorous, cholesterol, triglycerides,
HbA1c, glucose, and insulin. Ingestion of three doses of
25 g/day for 8 weeks resulted in symptoms of flatulence in
seven of the eight individuals and some diarrhea in six
individuals. The authors concluded that D-tag is a promising
sweetener without adverse effects observed in these trials.
Several studies were conducted to evaluate the gastroin-
testinal symptoms in humans; these were analyzed after the
consumption of 29 or 30 g of D-tag [19]. Nausea and diarrhea
were reported with an incidence of 15.1 and 31.5%, respec-
tively, in 73 healthy young men. The increase in flatulence
after D-tagatose was frequently reported in all studies and did
not diminish over a period of 15 days with the intake of 30 g in
a single dose daily. In most of the cases, moderate symptoms
were reported. However, the results suggest that the dose of
30 g ingested at a specific time can be superior to the dose that
should be recommended for ordinary use.
Another study compared the effect of carbohydrate in the
form of sucrose and D-tag on the plasma concentrations of
cholesterol, hyperglycemia, and atherosclerosis [6]. Mice of
both genders were fed with standard diet or a diet enriched
with sucrose or D-tag as a source of carbohydrates for
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16 weeks; both diets contained equivalent amounts (g/kg)
of macronutrients. The intake of food, body weight, and
diameter of adipocytes, concentration of cholesterol and
serum lipoproteins, and aortic atherosclerosiswere evaluated.
Immune-staining of macrophages and the contents of colla-
gen in the aortic root lesions were examined.
Mice fed with D-tag showed similar intake of energy,
body weight, blood sugar, and insulin, but the group fed
with sucrose exhibited a higher energy intake, obesity, and
hyperglycemia. There was an increment in the diameter
of adipocytes, the levels of cholesterol and plasma triglyc-
erides, atherosclerosis, immune-staining in macrophages,
and reduction in collagen content compared to mice that
consumed D-tag and the control group. These results show
that compared with sucrose the equivalent substitution of D-
tag as a carbohydrate in the diet does not lead to the same
proportion of obesity, hyperglycemia, hyperlipidemia, and
atherosclerosis [6].
A pilot study explored metabolic effects of D-tag [7]
administered orally at a dose of 15 g of D-tag 3 times a day
with food, in individuals with diabetes type 2 for 12 months.
None of the serious adverse effects were observed during
the treatment; 10 out of the 12 individuals recruited initially
experienced gastrointestinal side effects that tended to be
mild and transient. Average body weight decreased from
108.4 kg to 103.3 kg (𝑃 = 0.001). HbA1c did not have a
significant reduction; it went from 10.6% to 9.6% (𝑃 = 0.08).
HDL cholesterol levels increased progressively from a base
level of 30.5 to 41.7mg/dl in the 12 months in 6 individuals
who did not use lipid-modifying drugs during the study (𝑃 <
0.001). In conclusion, D-tag improved body weight and HDL
cholesterol in this pilot study.
Another trial [9] compared the effects of groups drug
(D-tag) and placebo (sucralose). The dose of D-tag was 15 g
dissolved in 125 to 250ml of water three times a day (TD); the
placebo dose was 1.5 g dissolved in 125 to 250ml of water TD.
The authors concluded that D-tag was effective in reducing
the level of HbA1c when it is administered for two months at
a dose of 15 g three times a day just before meals [9].
5. Glycemic Index and Glycemic
Load of Tagatose
Several studies have shown a positive effect after the intake
of tagatose in healthy individuals [9–11, 20] resulting in a
low GI [20], compared to glucose and white bread as a
reference food, glycemic index of D-tagatose was 3 and 4,
respectively. While investigating the GI of other sweeteners
like maltitol (=26), xylitol (=8), or isomaltulose (=32) [21], it
is observed that D-tag has less value even when compared to
sweetener blends composed of polydextrose and sorbitol (=7)
[20]. On the other hand, there is evidence of a null or very
low glycemic load GL (=0), compared to the value reported
for maltitol (GL = 3), xylitol (=1), isomaltulose (=3), or the
mixture of sorbitol and polydextrose (=1) [20]. It is known
that the indicators of GI and GL should be done initially in
healthy individuals to obtain ametabolic reference compared
with diabetic individuals [22]. Recognizing that the glycemic
variability is very high [23] and specific according to the type
of product or food [24], these studies should be extendedwith
more frequency in patients with diabetes type 2 in order to
compare differences in the stability of the glycemic curve and
get the value of these indicators in individuals with this type
of pathology [25, 26].
6. New Approaches in the Production and
Biotechnology Usefulness of Tagatose
The potential applications of this monosaccharide in the
pharmaceutical industry and the agri-food market have
reached a boom [27]. However, the use of D-tag is limited
by its high production cost [28]. Compared to the intracel-
lular enzymes, extracellular route is an interesting strategy
to increase the adequacy of biocatalysts [26]. Numerous
studies [28–31] have focused on this objective; recently a
gene (TM0416) encoding protein D-tag 3-epimerase from
a hyperthermophile marine bacterium has been studied;
this metalloenzyme showed an unusual high activity for the
epimerization of D-tag to D-sorbose, advance that could be
functionally classified in the production of unusual sugars
[30] and an alternative to produce vitamin C [28, 30].
Regarding its healthy prebiotic effect, it is known that the
chemical structure of tagatose must not be altered during
the processing and storage of food [27]. In this regard,
several studies have evaluated the thermal stability of this
sweetener in milk and lemonade in different concentrations,
concluding that this monosaccharide can be used in the for-
mulation of drinks for people with diabetes with a minimum
chance of degradation and very low loss of prebiotic activity
[32, 33].
Another recent investigation [34] highlighted the poten-
tial of the Lb. casei to reduce the accumulation of galactose
in fermented milk by the metabolic pathway tagatose-6-
phosphate (T6-P) specific for this species; this process, facing
the residual difficulties caused by lactose and galactose in
fermented dairy food, would be a potential alternative.These
wonderful advances in food technology make this molecule
an ideal sweetener in functional products for patients with
diabetes [26, 32, 33], with the ability to positively affect the
intestinal microbiota of these patients, making its consump-
tion more interesting and useful in a little explored area [34–
42].
7. Conclusion
After a decade of studies, tagatose became generally recog-
nized as a safe product to be used in food and beverages
under FDA Regulation of The United States. A subsequent
trial that lasted 14 months confirmed its potential use to treat
type 2 diabetes, showing great promise for inducing weight
loss and increased cholesterol of high density lipoproteins, as
well as its importance for the control of diabetes. There are
no current therapies for type 2 diabetes that provide these
benefits. Several studies indicate that predominant side effects
of tagatose are gastrointestinal disorders only associated with
excessive consumption, effects that do not exceed a specific
period of 2 weeks, and these have been only observed after
the consumption of high doses of tagatose.
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